TP53 and neoplasm: A current clinical trial in development through the Pediatric Neuro Oncology Consortium (PNOC) will allocate treatment based on TP53 status where patients with WT TP53 CPC will receive conventional ICE chemotherapy with or without focal RT and maintenance therapy, while patients with altered TP53 tumor or with germline mutation (high risk) will undergo consolidation with HDC followed by maintenance chemotherapy without adjuvant RT [Lafay-Cousin personal communication].